Propranolol Injection |
Inderal IV |
Clinical Trial: A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children with Cystic Fibrosis
This study is currently recruiting patients.
|
Purpose
This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: Nutropin AQ [somatropin (DNA origin) injection] | Phase II |
MedlinePlus related topics: Cystic Fibrosis
Genetics Home Reference related topics: cystic fibrosis
Study Type: Interventional
Study Design: Treatment
Official Title: A Phase II, Multicenter, randomized, controlled, open-label study of the safety and efficacy of Nutropin AQ [somatropin (DNA origin) injection] for the treatment of growth restriction in children with cystic fibrosis
Eligibility
Ages Eligible for Study: 5 Years - 13 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Ability of parent or legal guardian to provide written informed consent and, if applicable, pediatric assent and compliance with study assessments for the full duration of the study
- Diagnosis of CF by sweat or genetic testing
- Between the ages of 5 and 12 years for girls and 5 and 13 years for boys
- Ability to perform pulmonary function tests in a reproducible manner, per American Thoracic Society guidelines for spirometry
- Height <10th percentile for age and sex
- Prepubertal, Tanner Stage 1
- Bone age of the non-dominant hand and wrist obtained no more than 6 months prior to study entry (bone age must be <10 years for girls and <11 years for boys as read using the method of Greulich and Pyle)
- Adequate caloric intake (following the CFF guidelines is encouraged)
- Normal thyroid function
Exclusion Criteria:
- Prior or current rhGH use
- History of short stature due to GHD
- History of glucose intolerance (impaired glucose tolerance) or CF related diabetes (CFRD)
- Infection with Burkholderia cepacia
- Qualitative change in antibiotic treatment (e.g., for exacerbation of lung infection) within 14 days of study entry
- Hospitalization or treatment with systemic corticosteroids during the 30 days prior to study entry
- Inability to adhere to previously documented adequate nutrition
- Active neoplasia
- Use of any investigational drug within 30 days of study enrollment
- Subjects who require, as part of the their medical care, scheduled elective hospitalizations for IV antibiotic therapy
Location and Contact Information
Alaska
Pediatric Breathing Disorders Clinic, Anchorage, Alaska, 99508, United States; Recruiting
Arkansas
Pediatric and Pulmonology Research, Inc., Fort Smith, Arkansas, 72903, United States; Recruiting
California
Kaiser Hospital, Oakland, California, 94611, United States; Recruiting
Children's Hospital of Los Angeles, Los Angeles, California, 90027, United States; Recruiting
University of California, San Diego, San Diego, California, 92123, United States; Recruiting
Florida
Pediatric Pulmonary Associates, St. Petersburg, Florida, 33701, United States; Recruiting
Nemours Children's Clinic, Pensacola, Florida, 32504, United States; Recruiting
Nemours Children's Clinic, Orlando, Florida, 32806, United States; Recruiting
Illinois
Chicago Cystic Fibrosis Specialists, Glenview, Illinois, 60025, United States; Recruiting
Massachusetts
Boston Children's Hospital, Boston, Massachusetts, 02115, United States; Recruiting
Michigan
University of Michigan Health System, Ann Arbor, Michigan, 48109, United States; Recruiting
Missouri
Washington University, St. Louis, Missouri, 63110, United States; Recruiting
Nebraska
University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States; Recruiting
New Jersey
Saint Peter's University Hospital, New Brunswick, New Jersey, 08901, United States; Recruiting
New York
SUNY Health Science Center, Syracuse, New York, 13210, United States; Recruiting
North Carolina
Duke Pediatric Clinical Research Program, Durham, North Carolina, 27710, United States; Recruiting
Ohio
The Children's Medical Center, Dayton, Ohio, 45401, United States; Recruiting
Children's Hospital Medical Center of Akron, Akron, Ohio, 44308, United States; Recruiting
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States; Recruiting
Oklahoma
Baptist Medical Center, Oklahoma City, Oklahoma, 73112, United States; Recruiting
South Carolina
Pediatric Pulmonary Associates, Columbia, South Carolina, 29203, United States; Recruiting
Texas
University of Texas Health Center at Tyler, Tyler, Texas, 75708, United States; Recruiting
Childrens Medical Center, Dallas, Texas, 75235, United States; Recruiting
Utah
Intermountain Cystic Fibrosis Center, Salt Lake City, Utah, 84113, United States; Recruiting
More Information
Record last reviewed: April 2005
Last Updated: April 6, 2005
Record first received: March 11, 2004
ClinicalTrials.gov Identifier: NCT00079742
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Inderal IV (Drug Digest)
- Propranolol Injection (Drug Digest)

Not Signed In -


